Tourmaline Bio Inc
TRML20.940USD
-0.820-3.77%
交易中 （美东）报价延迟15分钟
537.83M总市值
亏损市盈率 TTM
关于 Tourmaline Bio Inc 公司
Tourmaline Bio, Inc. 是一家后期临床生物技术公司。该公司专注于开发变革性药物，以改善患有改变生活的免疫和炎症疾病患者的生活。该公司的初始候选产品是 TOUR006，这是一种完全人源单克隆抗体，可选择性结合白细胞介素 6 (IL-6)，这是一种参与许多自身免疫和炎症疾病发病机制的关键促炎细胞因子。TOUR006 是一种长效抗 IL-6 抗体，具有与 IL-6 的高结合亲和力、长半衰期和低观察到的免疫原性等特性。该公司还在开发 TOUR006 治疗甲状腺眼病 (TED) 和动脉粥样硬化性心血管疾病 (ASCVD) 的首两个适应症，目前正在考虑其他疾病。该公司专注于 TOUR006 的两条战略路径，其中第一条路径称为 FcRn+。其第二条战略路径是心血管炎症。
公司简介
公司代码TRML
公司名称Tourmaline Bio Inc
上市日期May 07, 2021
CEODr. Sandeep Kulkarni, M.D.
员工数量74
证券类型Ordinary Share
年结日May 07
公司地址27 West 24th Street, Suite 702
城市NEW YORK
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编10010
电话
网址https://www.tourmalinebio.com/
公司代码TRML
上市日期May 07, 2021
CEODr. Sandeep Kulkarni, M.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Parvinder Thiara
Mr. Parvinder Thiara
Independent Director
Independent Director
83.78K
--
Mr. Aaron Kantoff
Mr. Aaron Kantoff
Independent Director
Independent Director
45.39K
--
Dr. Sapna Srivastava, Ph.D.
Dr. Sapna Srivastava, Ph.D.
Independent Director
Independent Director
518.00
--
Mr. Brad Middlekauff, J.D.
Mr. Brad Middlekauff, J.D.
Chief Business Officer and General Counsel
Chief Business Officer and General Counsel
--
--
Dr. Susan Dana Jones, Ph.D.
Dr. Susan Dana Jones, Ph.D.
Chief Technology Officer
Chief Technology Officer
--
--
Mr. Ryan Robinson
Mr. Ryan Robinson
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Dr. Clay B. Siegall, Ph.D.
Dr. Clay B. Siegall, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Kevin Johnson, Ph.D.
Mr. Kevin Johnson, Ph.D.
Chief Regulatory Officer
Chief Regulatory Officer
--
--
Dr. Sandeep Kulkarni, M.D.
Dr. Sandeep Kulkarni, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Caley M. Castelein, M.D.
Dr. Caley M. Castelein, M.D.
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Parvinder Thiara
Mr. Parvinder Thiara
Independent Director
Independent Director
83.78K
--
Mr. Aaron Kantoff
Mr. Aaron Kantoff
Independent Director
Independent Director
45.39K
--
Dr. Sapna Srivastava, Ph.D.
Dr. Sapna Srivastava, Ph.D.
Independent Director
Independent Director
518.00
--
Mr. Brad Middlekauff, J.D.
Mr. Brad Middlekauff, J.D.
Chief Business Officer and General Counsel
Chief Business Officer and General Counsel
--
--
Dr. Susan Dana Jones, Ph.D.
Dr. Susan Dana Jones, Ph.D.
Chief Technology Officer
Chief Technology Officer
--
--
Mr. Ryan Robinson
Mr. Ryan Robinson
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 5月18日 周日
更新时间: 5月18日 周日
持股股东
股东类型
持股股东
持股股东
占比
RA Capital Management, LP
9.88%
Avoro Capital Advisors LLC
9.44%
Hydra LLC
6.63%
BlackRock Institutional Trust Company, N.A.
6.23%
TCG Crossover Management, LLC
5.75%
Other
62.07%
持股股东
持股股东
占比
RA Capital Management, LP
9.88%
Avoro Capital Advisors LLC
9.44%
Hydra LLC
6.63%
BlackRock Institutional Trust Company, N.A.
6.23%
TCG Crossover Management, LLC
5.75%
Other
62.07%
股东类型
持股股东
占比
Investment Advisor
28.62%
Hedge Fund
23.94%
Investment Advisor/Hedge Fund
20.66%
Venture Capital
14.33%
Corporation
11.58%
Individual Investor
10.35%
Research Firm
2.53%
Bank and Trust
0.30%
Pension Fund
0.16%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
265
28.92M
112.56%
-6.26M
2025Q1
278
29.06M
113.12%
-6.65M
2024Q4
267
27.86M
108.65%
-4.54M
2024Q3
254
27.28M
106.38%
-4.78M
2024Q2
248
27.58M
107.55%
-803.47K
2024Q1
238
26.92M
105.10%
+7.92M
2023Q4
193
17.05M
91.28%
+8.99M
2023Q3
170
3.58M
159.92%
-896.76K
2023Q2
178
3.46M
81.64%
-454.91K
2023Q1
158
3.62M
86.22%
-261.50K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
RA Capital Management, LP
2.54M
9.88%
--
--
Mar 31, 2025
Avoro Capital Advisors LLC
2.42M
9.44%
+202.78K
+9.13%
Mar 31, 2025
Hydra LLC
1.70M
6.63%
+500.00K
+41.59%
Dec 31, 2023
BlackRock Institutional Trust Company, N.A.
1.60M
6.23%
-14.27K
-0.88%
Mar 31, 2025
TCG Crossover Management, LLC
1.48M
5.75%
--
--
Mar 31, 2025
QVT Financial LP
1.47M
5.74%
+762.09K
+107.14%
Mar 31, 2025
Pfizer Inc
1.27M
4.95%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
1.19M
4.62%
+84.69K
+7.68%
Mar 31, 2025
Blue Owl Capital Holdings LP
1.04M
4.04%
-42.21K
-3.91%
Mar 31, 2025
Castelein (Caley M.)
974.56K
3.79%
--
--
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
Virtus LifeSci Biotech Clinical Trials ETF
0.72%
ALPS Medical Breakthroughs ETF
0.28%
iShares Micro-Cap ETF
0.07%
Invesco Nasdaq Biotechnology ETF
0.05%
ProShares Ultra Nasdaq Biotechnology
0.05%
Fidelity Enhanced Small Cap ETF
0.04%
Avantis US Small Cap Equity ETF
0.04%
iShares Biotechnology ETF
0.03%
Nuveen ESG Small-Cap ETF
0.02%
iShares Russell 2000 Value ETF
0.02%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
占比0.72%
ALPS Medical Breakthroughs ETF
占比0.28%
iShares Micro-Cap ETF
占比0.07%
Invesco Nasdaq Biotechnology ETF
占比0.05%
ProShares Ultra Nasdaq Biotechnology
占比0.05%
Fidelity Enhanced Small Cap ETF
占比0.04%
Avantis US Small Cap Equity ETF
占比0.04%
iShares Biotechnology ETF
占比0.03%
Nuveen ESG Small-Cap ETF
占比0.02%
iShares Russell 2000 Value ETF
占比0.02%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Oct 19, 2023
Merger
10<1
Oct 19, 2023
Merger
10<1
Oct 19, 2023
Merger
10<1
Oct 19, 2023
Merger
10<1
公告日期
类型
比率
Oct 19, 2023
Merger
10<1
Oct 19, 2023
Merger
10<1
Oct 19, 2023
Merger
10<1
Oct 19, 2023
Merger
10<1
